TFX Teleflex Incorporated

Standard Bariatrics, Inc., now part of Teleflex, Awarded Bariatric Stapling Technology Agreement with Premier Inc.

Standard Bariatrics, Inc., now part of Teleflex, Awarded Bariatric Stapling Technology Agreement with Premier Inc.

WAYNE, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded a group purchasing organization (GPO) agreement with Premier®, Inc. for the Titan SGS® powered stapling device, expanding access to this innovative technology for surgeons affiliated with Premier.

The Titan SGS® device is a sterile, single patient use instrument used for longitudinal transection and resection of the gastric tissue for sleeve gastrectomy pouch creation.1 It is the only stapler available in the United States with a specific indication for sleeve pouch creation in bariatric procedures. The GPO agreement allows Premier members, at their discretion, the opportunity to take advantage of special pricing and terms pre-negotiated by Premier for the Titan SGS® device.

“It’s an honor to be selected as a supplier for Premier. They are committed to providing innovative medical devices to surgeons and healthcare providers. We are excited to work with them to provide the advanced technology of Titan SGS®,” said James Ferguson, President and General Manager, Surgical, Teleflex.

The Titan SGS® powered stapling device offers a range of benefits:

  • Shown to cut stapling time for a sleeve gastrectomy in half with one 55-second firing sequence2,3
  • Helps surgeons deliver a more consistent and repeatable gastric sleeve anatomy with the industry’s longest continuous staple line of 23cm with no overlapping staples3
  • Because it has been shown to take approximately half the time to create the staple line compared to existing short cartridge linear staplers,2,4 it can also potentially improve procedure time and operational efficiencies3,4

More than 6,000 sleeve gastrectomy procedures—laparoscopic and robotic-assisted—have been completed across the United States using Titan SGS® technology since its introduction to the market in 2021.

“We are thrilled Premier awarded Teleflex this contract for the Titan SGS®. We see this as another opportunity to put the transformational technology of Titan SGS® into the hands of bariatric surgeons across the country,” said Ronald Galovich, Vice President, Marketing & Sales, Surgical, Teleflex Incorporated.

Surgeons interested in learning more about Titan SGS® device or to request training can visit .

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,400 U.S. hospitals and 250,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit .

Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®, QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

About Standard Bariatrics, Inc.

Standard Bariatrics, Inc., now part of Teleflex, is focused on the development and commercialization of products for the surgical treatment of obesity. Driven by a passionate group of surgical innovators, the organization works hand in hand with bariatric surgeons to develop and release novel solutions designed to address the growing global epidemic of obesity. The team offers extensive experience in creating and bringing to market bariatric-related medical device technologies. They have a demonstrated record of achieving clinical excellence with economically responsible solutions for providers and their patients.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, Titan SGS, Standard Bariatrics, UroLift, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. © 2023 Teleflex Incorporated. All rights reserved.

References:

1510(k) No. K210278. 28 Apr 2021. Retrieved from

2Standard Bariatrics, Inc., Section 510(k) Premarket Notification Submission for Titan SGS. Prepared 28 Jan 2021.

3Salyer, C. E., Thompson, J., Hoffman, A., Burstein, M. D., Enochs, P., Watkins, B. M., Kuethe, J., & Goodman, M. D. (2022). Multisite Study of Titan SGS Stapler in longitudinal gastric resection. Surgical Endoscopy. /10.1007/s00464-022-09051-x

4Varban, O. A., Niemann, A., Stricklen, A., Ross, R., Ghaferi, A. A., Finks, J. F., & Dimick, J. B. (Aug 2017). Far from Standardized: Using Surgical Videos to Identify Variation in Technique for Laparoscopic Sleeve Gastrectomy. Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A, 27(8), 761–767.

Contacts:

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development

John Hsu, CFA

Vice President, Investor Relations



610-948-2836



EN
07/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Teleflex Inc: 5 directors

Five Directors at Teleflex Inc bought 5,500 shares at between 114.750USD and 115.860USD. The significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...

 PRESS RELEASE

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthc...

 PRESS RELEASE

Teleflex Reports Second Quarter Financial Results and Full Year 2025 O...

Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch